INCA033989 Clinical Trials
3 recruitingDrug
Phase 13
Showing 1–3 of 3 trials
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation290 enrolled13 locationsNCT06034002
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation225 enrolled29 locationsNCT05936359
Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
Healthy Participants
Incyte Corporation72 enrolled1 locationNCT07448155